CagriSema for Type 2 Diabetes Mellitus
Phase-Based Progress Estimates
Effectiveness
Safety
Type 2 Diabetes Mellitus+5 More
Cagrilintide - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance. The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.
Eligible Conditions
- Type 2 Diabetes Mellitus
- Overweight
- Obesity
- Diabetes Mellitus
Treatment Effectiveness
Effectiveness Progress
This is further along than 85% of similar trials
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: From baseline (week 0) to end of treatment (week 68)
Week 68
Achievement of greater than or equal to 5% weight reduction
Achievement of ≥ 20% weight reduction
Body Weight Changes
Change in Quality Of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function score
Change in Short Form-36 Version 2.0 (SF-36v2) Physical Functioning score
Change in Systolic Blood Pressure (SBP)
Change in waist circumference
Week 20
Relative change in body weight
Trial Safety
Safety Progress
This is further along than 85% of similar trials
Trial Design
2 Treatment Groups
CagriSema
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group
1200 Total Participants · 2 Treatment Groups
Primary Treatment: CagriSema · Has Placebo Group · Phase 3
CagriSemaExperimental Group · 2 Interventions: Cagrilintide, Semaglutide · Intervention Types: Drug, Drug
PlaceboPlaceboComparator Group · 2 Interventions: Placebo cagrilintide, Placebo semaglutide · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cagrilintide
2021
Completed Phase 1
~40
Semaglutide
2019
Completed Phase 4
~5560
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: from baseline (week 0) to end of treatment (week 68)
Who is running the clinical trial?
Novo Nordisk A/SLead Sponsor
1,390 Previous Clinical Trials
2,292,403 Total Patients Enrolled
55 Trials studying Type 2 Diabetes Mellitus
12,427 Patients Enrolled for Type 2 Diabetes Mellitus
Clinical Transparency (dept. 2834)Study DirectorNovo Nordisk A/S
36 Previous Clinical Trials
54,901 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 7 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have a body mass index (BMI) greater than or equal to 27.0 kg/m^2.
You have type 2 diabetes mellitus greater than or equal to 180 days before screening.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments